Frontiers in Pharmacology (Jan 2022)
Corrigendum: COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis
- Zewen Chu,
- Xin Shi,
- Gaoyang Chen,
- Xuejun He,
- Yayun Qian,
- Haibo Wang,
- Li Tao,
- Yanqing Liu,
- Wei Jiang,
- Jue Chen,
- Jue Chen
Affiliations
- Zewen Chu
- Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
- Xin Shi
- Department of Oncology, The Second People’s Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China
- Gaoyang Chen
- Department of Oncology, The Second People’s Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China
- Xuejun He
- Department of Oncology, The Second People’s Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China
- Yayun Qian
- Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
- Haibo Wang
- Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
- Li Tao
- College of Environmental Science and Engineering, Marine Science and Technology Institute, Yangzhou University, Yangzhou, China
- Yanqing Liu
- Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
- Wei Jiang
- College of Environmental Science and Engineering, Marine Science and Technology Institute, Yangzhou University, Yangzhou, China
- Jue Chen
- Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China
- Jue Chen
- Department of Oncology, The Second People’s Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China
- DOI
- https://doi.org/10.3389/fphar.2021.831941
- Journal volume & issue
-
Vol. 12
Abstract
No abstracts available.Keywords